title: Outcomes in patients who have failed endoscopic therapy for dysplastic Barrett's metaplasia or early esophageal cancer.
abstract: BACKGROUND
  Endoscopic therapy (ablation ± mucosal resection) for esophageal high-grade dysplasia (HGD) or intramucosal carcinoma has demonstrated promising results. Little is known about patients who have persistent or progressive disease despite endotherapy. We compared patients who had successful eradication of their disease with those in whom endotherapy failed to try to identify factors predictive of failure and outcomes after salvage therapy.
  
  
  METHODS
  We performed a single-institution retrospective review of patients treated with endotherapy from 2007 to 2012.
  
  
  RESULTS
  Thirty-eight patients underwent endotherapy: 28 had successful eradication of their disease and endotherapy failed in 10 patients. Patients in whom endotherapy failed were more likely to have high-grade dysplasia (HGD) on initial endoscopy, nodules or ulcers, multifocal dysplasia, and persistent nondysplastic Barrett's metaplasia. Patients in whom endotherapy failed also underwent significantly more endotherapy sessions. Seven patients had persistent dysplasia or progression to cancer, and 3 patients had complete eradication of HGD but presented with intramucosal carcinoma an average of 15 months after eradication. The 10 patients in whom endotherapy failed underwent salvage therapy with esophagectomy (7 patients), definitive chemoradiotherapy (1 patient), and endotherapy (2 patients). Patients treated with esophagectomy were disease free at a mean of 25 months postoperatively.
  
  
  CONCLUSIONS
  HGD on initial endoscopy, multifocal dysplasia, mucosal abnormalities, and failure to eradicate nondysplastic Barrett's metaplasia were associated with failure of endotherapy. Patients with these characteristics should be considered at higher risk for treatment failure, and earlier consideration should be given to esophagectomy if there is persistent, progressive, or recurrent neoplasia. Clinical outcomes are good, even after salvage therapy. Continued endoscopic surveillance is mandatory after successful endotherapy because of the risk of recurrent disease.
authors.affiliation: Division of Thoracic Surgery, Swedish Cancer Institute and Medical Center, Seattle, Washington, USA.
authors.forename: Ben M
authors.initials: BM
authors.lastname: Hunt
authors.forename: Brian E
authors.initials: BE
authors.lastname: Louie
authors.forename: Drew B
authors.initials: DB
authors.lastname: Schembre
authors.forename: Anthony G
authors.initials: AG
authors.lastname: Bohorfoush
authors.forename: Alexander S
authors.initials: AS
authors.lastname: Farivar
authors.forename: Ralph W
authors.initials: RW
authors.lastname: Aye
mesh_terms: D000368:Aged; D001471:Barrett Esophagus / Q000601:surgery*; D004938:Esophageal Neoplasms / Q000601:surgery*; D016629:Esophagectomy; D004945:Esophagoscopy; D005260:Female; D006801:Humans; D008297:Male; D008679:Metaplasia; D009367:Neoplasm Staging; D012189:Retrospective Studies